Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 6 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.
Under the programme initiated 4 August 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 5 August 2021 to 1 November 2021.
Since the announcement 30 August 2021, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 1,377,000 | 896,729,927 | |
| 30 August 2021 | 81,000 | 640.68 | 51,895,198 |
| 31 August 2021 | 81,000 | 639.26 | 51,779,795 |
| 1 September 2021 | 80,000 | 630.07 | 50,405,765 |
| 2 September 2021 | 81,000 | 634.31 | 51,378,980 |
| 3 September 2021 | 81,000 | 630.23 | 51,048,428 |
| Accumulated under the programme | 1,781,000 | 1,153,238,093 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 19,301,886 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12-month period beginning 3 February 2021. As of 3 September 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 20,495,414 B shares at an average share price of DKK 489.85 per B share equal to a transaction value of DKK 10,039,597,070.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
| Media: | ||
| Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com |
| Michael Bachner (US) | +1 609 664 7308 | mzyb@novonordisk.com |
| Investors: | ||
| Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
| David Heiberg Landsted | +45 3077 6915 | dhel@novonordisk.com |
| Mark Joseph Root (US) | +1 848 213 3219 | mjhr@novonordisk.com |
Company announcement No. 56 / 2021
Attachment
